Tom Martin

1.6k total citations
22 papers, 371 citations indexed

About

Tom Martin is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Tom Martin has authored 22 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Tom Martin's work include Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (10 papers) and CAR-T cell therapy research (8 papers). Tom Martin is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (10 papers) and CAR-T cell therapy research (8 papers). Tom Martin collaborates with scholars based in United States, Belgium and Spain. Tom Martin's co-authors include Melissa Alsina, Rubén Niesvizky, Mei Huang, David S. Siegel, Michael Wang, William Bensinger, Robert Z. Orlowski, Edward Kavalerchik, Brian F. Habbick and Lloyd E. Damon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Tom Martin

21 papers receiving 361 citations

Peers

Countries citing papers authored by Tom Martin

Since Specialization

Citations

This map shows the geographic impact of Tom Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Martin more than expected).

Fields of papers citing papers by Tom Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Martin. The network helps show where Tom Martin may publish in the future.

Co-authorship network of co-authors of Tom Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Martin. A scholar is included among the top collaborators of Tom Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Martin. Tom Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). 2025 ·Journal of Clinical Oncology ·Peter M. Voorhees, Tom Martin, Yi Lin, Adam D. Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesús G. Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Huijun Li, Rocío Montes de, (unknown), Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath	1
2	MM-382 iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Tom Martin, Noopur Raje, Jesús F. San Miguel, Krina K. Patel, (unknown), Christine Lui, Carolyn C. Jackson, Christopher R. Heery, Niels W.C.J. van de Donk, Jesús G. Berdeja, María‐Victoria Mateos	1
3	P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL. 2023 ·HemaSphere ·David H. Vesole, Jesús G. Berdeja, Jeffrey Matous, Suzanne Trudel, (unknown), Pamela N. Münster, (unknown), Benjamin Sun, Tom Martin	0
4	Disease Monitoring In Multiple Myeloma 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Tom Martin, Noemí Puig, Bruno Paiva, Saad Z. Usmani, Shaji Kumar, Jesús F. San Miguel	1
5	P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS 2023 ·HemaSphere ·Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, Sonja Zweegman, (unknown), (unknown), Tom Martin, Cesar Rodriguez, Ajay K. Nooka, (unknown), Sheri Skerget, (unknown), Arnob Banerjee, Katherine Chastain, Alfredo Perales‐Puchalt, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Raluca Verona, Niels W.C.J. van de Donk	2
6	P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) 2023 ·HemaSphere ·Surbhi Sidana, Philippe Moreau, Alfred L. Garfall, Manisha Bhutani, Albert Oriol, Ajay K. Nooka, Tom Martin, (unknown), María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Niels W.C.J. van de Donk	6
7	S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA 2023 ·HemaSphere ·Nikhil C. Munshi, Tom Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Yi Lin, Elizabeth O’Donnell, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, (unknown), Lida Pacaud, Sundar Jagannath	9
8	BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study 2023 ·Blood ·Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Hakan Koçoğlu, Tara Gregory, Adriana Rossi, Tom Martin, Daniel Egan, Luciano J. Costa, (unknown), Yanping Chen, Shaoyi Li, Lisa M. Kelly, (unknown), Safiyyah Ziyad, (unknown), Allison Kaeding, Michael R. Burgess, Jesús G. Berdeja	32
9	S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS 2023 ·HemaSphere ·Nizar J. Bahlis, Katja Weisel, María‐Victoria Mateos, Hartmut Goldschmidt, Tom Martin, Daniel Morillo, Donna Reece, Paula Rodríguez‐Otero, Manisha Bhutani, Anita D’Souza, Albert Oriol, (unknown), Bhagirathbhai Dholaria, Kalpana Bakshi, Lijuan Kang, (unknown), (unknown), Ralph Wäsch, Niels W.C.J. van de Donk, Ajai Chari	6
10	Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Katja Weisel, Amrita Krishnan, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Tzu‐Min Yeh, Arnob Banerjee, Fevzi Yalniz, Tonia Nesheiwat, Suzy Van Sanden, Joris Diels, Satish Valluri, Saad Z. Usmani, Jesús G. Berdeja, Sundar Jagannath, Tom Martin	10
11	Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA 2022 ·Haematologica ·Tom Martin, Paul G. Richardson, Thierry Façon, Philippe Moreau, Aurore Perrot, Ivan Špıčka, Kamlesh Bisht, (unknown), (unknown), Sandrine Macé, Helgi van de Velde, Kenshi Suzuki	22
12	Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma 2021 ·Current Medical Research and Opinion ·Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Martin Vogel, Carolyn C. Jackson, William Deraedt, Hong Tian, Tzu‐Min Yeh, Arnob Banerjee, Lida Pacaud, (unknown), (unknown), Chris Cameron, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo	34
13	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies 2021 ·Expert Review of Hematology ·Kamlesh Bisht, Brian A. Walker, Shaji Kumar, Ivan Špıčka, Philippe Moreau, Tom Martin, Luciano J. Costa, Joshua Richter, Taro Fukao, Sandrine Macé, Helgi van de Velde	23
14	New toxicity testing of PQ grass allergy immunotherapy to support product development 2019 ·Journal of Applied Toxicology ·Paul Baldrick, (unknown), Matthew D. Heath, Murray Skinner, Tom Martin, C.G. Gray	2
15	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary 2019 ·Journal of Oncology Practice ·Joseph Mıkhael, Nofisat Ismaila, Tom Martin	7
16	KIR and HLA Genotypes Predictive of Low-Affinity Interactions Are Associated with Lower Relapse in Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia 2015 ·The Journal of Immunology ·(unknown), Justin Greene, Jimmy J. Hwang, Juan Du, Lloyd E. Damon, Tom Martin, Jeffrey M. Venstrom	30
17	Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma. 2013 ·Cancer Research ·Byron Hann, Ti Cai, Donghui Wang, (unknown), Blake T. Aftab, Tom Martin, Jeffrey L. Wolf	2
18	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma 2013 ·Blood ·Michael Wang, Tom Martin, William Bensinger, Melissa Alsina, David S. Siegel, Edward Kavalerchik, Mei Huang, Robert Z. Orlowski, Rubén Niesvizky	103
19	High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia 2003 ·Biology of Blood and Marrow Transplantation ·(unknown), Lloyd E. Damon, Paul D. Varosy, Willis H. Navarro, Tom Martin, Curt A. Ries, Charles Linker	22
20	Tularemia in Canada with a focus on Saskatchewan. 1982 ·PubMed ·Tom Martin, Ian Holmes, Gary A. Wobeser, (unknown), (unknown)	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact